OBJECTIVES: The objective of this study was to develop a simultaneous population pharmacokinetic (PK) model to describe atazanavir/ritonavir (ATV/RTV) PK (300/100 mg) and to assess the effect of RTV dose reduction on ATV PK. Simulations of ATV concentration-time profiles were performed at doses of ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg once daily. METHODS: A total of 288 ATV and 312 RTV plasma concentrations from 30 patients were included to build a population PK model using the stochastic approximation expectation maximization algorithm implemented in MONOLIX 3.2 software. RESULTS: A one-compartment model with first-order absorption and lag-time best described the data for both drugs in the final simultaneous model. A maximum-effect model in which RTV inhibited the elimination of ATV was used to describe the relationship between RTV concentrations and ATV clearance (CL/F). An RTV concentration of 0.22 mg/L was associated with 50% maximum inhibition of ATV CL/F. The population prediction of ATV CL/F in the absence of RTV was 16.6 L/h (relative standard error, 7.0%), and the apparent volume of distribution and absorption rate constant were 106 L (relative standard error, 8%) and 0.87 per hour (fixed), respectively. Simulated average ATV trough concentrations at ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg once daily were 45%, 63%, and 33% lower, respectively, than that of the standard dose. CONCLUSION: Although simulated median ATV trough concentrations after dose reductions were still more than the ATV minimum effective concentration (2.9-, 1.9-, and 3.6-fold for ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg, respectively); our modeling predicted a high proportion of individuals with subtherapeutic trough concentrations on the 200/50 mg dose. This suggests that 300/50 mg and 200/100 mg dosing are preferred candidate regimens in future clinical studies.
OBJECTIVES: The objective of this study was to develop a simultaneous population pharmacokinetic (PK) model to describe atazanavir/ritonavir (ATV/RTV) PK (300/100 mg) and to assess the effect of RTV dose reduction on ATV PK. Simulations of ATV concentration-time profiles were performed at doses of ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg once daily. METHODS: A total of 288 ATV and 312 RTV plasma concentrations from 30 patients were included to build a population PK model using the stochastic approximation expectation maximization algorithm implemented in MONOLIX 3.2 software. RESULTS: A one-compartment model with first-order absorption and lag-time best described the data for both drugs in the final simultaneous model. A maximum-effect model in which RTV inhibited the elimination of ATV was used to describe the relationship between RTV concentrations and ATV clearance (CL/F). An RTV concentration of 0.22 mg/L was associated with 50% maximum inhibition of ATV CL/F. The population prediction of ATV CL/F in the absence of RTV was 16.6 L/h (relative standard error, 7.0%), and the apparent volume of distribution and absorption rate constant were 106 L (relative standard error, 8%) and 0.87 per hour (fixed), respectively. Simulated average ATV trough concentrations at ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg once daily were 45%, 63%, and 33% lower, respectively, than that of the standard dose. CONCLUSION: Although simulated median ATV trough concentrations after dose reductions were still more than the ATV minimum effective concentration (2.9-, 1.9-, and 3.6-fold for ATV/RTV 300/50 mg, 200/50 mg, and 200/100 mg, respectively); our modeling predicted a high proportion of individuals with subtherapeutic trough concentrations on the 200/50 mg dose. This suggests that 300/50 mg and 200/100 mg dosing are preferred candidate regimens in future clinical studies.
Authors: Laura Dickinson; Lesley Robinson; John Tjia; Saye Khoo; David Back Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2005-10-13 Impact factor: 3.205
Authors: Chao Zhang; Helen McIlleron; Yuan Ren; Jan-Stefan van der Walt; Mats O Karlsson; Ulrika S H Simonsson; Paolo Denti Journal: Antivir Ther Date: 2012
Authors: Lauro J Waters; Graeme Moyle; Stefano Bonora; Antonio D'Avolio; Laura Else; Sundhiya Mandalia; Anton Pozniak; Mark Nelson; Brian Gazzard; David Back; Marta Boffito Journal: Antivir Ther Date: 2007
Authors: M Markowitz; M Saag; W G Powderly; A M Hurley; A Hsu; J M Valdes; D Henry; F Sattler; A La Marca; J M Leonard Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: Marta Boffito; Michael Kurowski; Guido Kruse; Andrew Hill; Andrew A Benzie; Mark R Nelson; Graeme J Moyle; Brian G Gazzard; Anton L Pozniak Journal: AIDS Date: 2004-06-18 Impact factor: 4.177
Authors: Charles S Venuto; Katie Mollan; Qing Ma; Eric S Daar; Paul E Sax; Margaret Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Gene D Morse Journal: J Antimicrob Chemother Date: 2014-08-25 Impact factor: 5.790
Authors: Kun Wang; David Z D'Argenio; Edward P Acosta; Anandi N Sheth; Cecile Delille; Jeffrey L Lennox; Corenna Kerstner-Wood; Ighovwerha Ofotokun Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447
Authors: José Moltó; Javier A Estévez; Cristina Miranda; Samandhy Cedeño; Bonaventura Clotet; Marta Valle Journal: Br J Clin Pharmacol Date: 2016-09-13 Impact factor: 4.335
Authors: J B Dumond; J Chen; M Cottrell; C R Trezza; Hma Prince; C Sykes; C Torrice; N White; S Malone; R Wang; K B Patterson; N E Sharpless; A Forrest Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-12-29